商品描述
This edited volume presents a thorough exploration of the fundamentals, concepts and methods of nanocrystal development for targeted drug delivery. In pharmaceutical and biomedical sciences, addressing poor bioavailability is of paramount importance in drug development. Innovative strategies are being employed to enhance the solubility, dissolution rate, and physiochemical properties of Biopharmaceutical Classification System (BCS) II and IV drugs. Drug nanocrystals have emerged as a solution by leveraging the crystalline nature of drugs to address critical challenges. This carrier-free colloidal drug delivery system operates at the nano-size range, where the crystalline drug particle core is enveloped by a stabilizing agent (surfactant/polymer). However, selecting a stabilizer remains a persistent challenge for certain drug molecules. This book aims to address the critical aspects of nanocrystal technology by covering classification, stabilizer selection criteria, bottom-up and bottom-down preparation, characterization methods, recent advancements, toxicological considerations, regulatory insights, and clinical status of drug nanocrystals. The book advocates the implementation of a quality by design (QbD) and a design of experimentation approach to minimize errors in product optimization and validation for targeted drug delivery systems. The book comprises of contributions from global experts including renowned formulators, researchers, and academicians ensuring diverse insights and expertise across various specializations. The book is primarily targeted at academic and industrial researchers, Ph.D. and postdoctoral research fellows, formulation scientists, and bio-medical professionals.
商品描述(中文翻譯)
本編輯書籍深入探討了納米晶體開發的基本原理、概念和方法，以實現靶向藥物傳遞。在藥學和生物醫學科學中，解決藥物的低生物利用度在藥物開發中至關重要。創新的策略正在被採用，以提高生物藥物分類系統（Biopharmaceutical Classification System, BCS）II和IV類藥物的溶解度、溶解速率和理化特性。藥物納米晶體作為一種解決方案，利用藥物的晶體特性來應對關鍵挑戰。這種無載體的膠體藥物傳遞系統在納米尺寸範圍內運作，其中晶體藥物顆粒核心被穩定劑（表面活性劑/聚合物）包裹。然而，對於某些藥物分子來說，選擇穩定劑仍然是一個持續的挑戰。
本書旨在通過涵蓋分類、穩定劑選擇標準、自下而上和自上而下的製備、表徵方法、近期進展、毒理考量、法規見解以及藥物納米晶體的臨床狀態，來解決納米晶體技術的關鍵方面。本書提倡實施設計質量（Quality by Design, QbD）和實驗設計的方法，以最小化靶向藥物傳遞系統產品優化和驗證中的錯誤。
本書匯集了來自全球的專家貢獻，包括知名的配方師、研究人員和學者，確保在各個專業領域中提供多樣的見解和專業知識。本書主要針對學術和工業研究人員、博士及博士後研究員、配方科學家和生物醫學專業人士。
作者簡介
Dr. Neelesh Kumar Mehra is working in the Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research (NIPER), Hyderabad, India. He earned PhD from Dr. H.S. Gour University, Sagar and PostDoc from Irma Lerma Rangel College of Pharmacy, Texas A and M Health Science Centre, Kingsville, TX, USA. He served as Manager in Product Development, Sentiss Research Centre, Sentiss Pharma Pvt Ltd. Gurgaon for development, scale-up and technology transfer of complex ophthalmic, inhalation and optic pharmaceutical products. He received 'TEAM AWARD' for successful commercialization of Ophthalmic Suspension product. He has authored more than 140 peer-reviewed publications in high repute International Journals, and >50 book chapter contributions. He has 04 granted and 05 filed patent on manufacturing process and composition to improved therapeutic efficacy for topical delivery. He has supervised 05 PhD research scholar and 36 MS Students for their research work. Currently, he is mentoring 10 PhD and 05 M.S. students for dissertations/research projects. He has completed numerous extramural research projects from different government agencies on cancer, diabetic wound and ophthalmic formulation development. He has received numerous outstanding awards including Young Scientist and Team Awards for their research output. He is a peer reviewer of various international Journals and publishers. He recently published edited book on Multifunctional nanocarriers, Biopharmaceutical and nanotechnology. He has rich research and teaching experience in the formulation and development of complex, innovative ophthalmic and injectable biopharmaceutical products including micro- and nanotechnologies for regulated market and so on. According to announcement by the Stanford University Scientists based on the database and basis of standardized citation indicators, Dr. Mehra name is included in top 2% scientists in the world in the area of Pharmacology and Pharmacy, consecutively for 3 years. Dr. Kuldeep K. Bansal, an adjunct professor, has been affiliated with the Department of Pharmacy at Åbo Akademi University in Turku, Finland, since 2017. He commenced his tenure at Åbo Akademi University as a Postdoctoral researcher, focusing on the development of polymer-based nano-formulations. During his tenure, he produced a novel polymer named poly(jasmine lactone) (PJL) and pushing technology forward to identify commercial pathways for drug delivery applications. He obtained his PhD from the University of Nottingham, United Kingdom in 2015. His study primarily focuses on the production of novel polymers for enhanced delivery of toxic and hydrophobic pharmaceuticals. He possesses experience in working with pharmaceutical companies in the research and development and quality assurance sectors. He has produced over 40 peer-reviewed publications in reputable international journals along with more than 4 book chapters. He serves as a peer reviewer for numerous international journals and publishers. He possesses one awarded patent on Polymer and composition from renewable sources. He is presently supervising four PhD students and has overseen more than ten MS students in their dissertations and research projects.
作者簡介(中文翻譯)
尼勒什·庫馬·梅赫拉博士目前在印度海得拉巴的國立藥學教育與研究所（NIPER）藥劑學系工作。他在德拉H.S. Gour大學獲得博士學位，並在美國德克薩斯A&M健康科學中心的Irma Lerma Rangel藥學院完成博士後研究。他曾擔任Sentiss Pharma Pvt Ltd. Gurgaon的產品開發經理，負責複雜的眼科、吸入和光學藥品的開發、放大和技術轉移。他因成功商業化眼科懸浮液產品而獲得「團隊獎」。他在高聲望的國際期刊上發表了超過140篇同行評審的論文，並貢獻了超過50章書籍章節。他擁有4項已授權和5項已申請的專利，涉及改進局部給藥的製造過程和組成，以提高治療效果。他指導了5名博士研究生和36名碩士生的研究工作。目前，他正在指導10名博士生和5名碩士生的論文/研究項目。他已完成來自不同政府機構的多個外部研究項目，涉及癌症、糖尿病傷口和眼科配方的開發。他獲得了多項卓越獎項，包括青年科學家獎和團隊獎，以表彰其研究成果。他是多個國際期刊和出版商的同行評審人。
他最近出版了關於多功能納米載體、生物製藥和納米技術的編輯書籍。他在複雜、創新眼科和注射生物製藥產品的配方和開發方面擁有豐富的研究和教學經驗，包括針對受管制市場的微型和納米技術等。
根據斯坦福大學科學家的公告，基於數據庫和標準化引用指標，梅赫拉博士在藥理學和藥學領域連續三年被列入全球前2%的科學家名單。
庫爾迪普·K·班薩爾博士是一位兼任教授，自2017年以來一直與芬蘭土爾庫的阿博學院（Åbo Akademi University）藥學系有關聯。他在阿博學院的任期始於博士後研究員，專注於聚合物基納米配方的開發。在任期內，他研發了一種名為聚（茉莉花內酯）（PJL）的新型聚合物，並推進技術以識別藥物傳遞應用的商業途徑。他於2015年在英國諾丁漢大學獲得博士學位。他的研究主要集中在生產新型聚合物，以增強有毒和疏水性藥物的傳遞。他在製藥公司的研究與開發及質量保證部門擁有工作經驗。他在知名國際期刊上發表了超過40篇同行評審的論文，以及超過4章書籍章節。他是多個國際期刊和出版商的同行評審人。
他擁有一項來自可再生資源的聚合物及其組成的專利。他目前正在指導四名博士生，並已監督超過十名碩士生的論文和研究項目。
